In 2020, the US government launched a number of drug importation-focused initiatives aimed at addressing high drug costs in the US. In September, as part of its Safe Importation Action Plan, FDA issued a final rule allowing importation of certain prescription drugs from Canada, along with a final guidance for importing prescription drugs originally intended for foreign markets. The Most Favored Nation executive order, released in November, limits the reimbursement rates for CMS to rates paid by other countries. In this webinar, panelists will take stock of the new state of drug importation, especially in light of COVID-19, and its potential impact to the US drug market. The discussion will include an in-depth review of both actions, focusing on the Safe Importation Action Plan and how Canadian regulators and manufacturers have responded, the risks of foreign unapproved drugs, and the potential impact to US pricing, approvals, and innovation.
- +$100 for nonmembers
Internet Explorer and Microsoft Edge are not supported by the checkout process.
Please use Chrome, Firefox, or Safari. If you are unable to use these browsers, please contact us at 202-371-1420 or [email protected] and we will assist you.
David Certner, Legislative Counsel and Director, Legislative Policy for Government Affairs, AARP
Jeffrey K. Francer, Senior Vice President and General Counsel, Association for Accessible Medicines and Member, FDLI Board of Directors
Eileen M. McMahon, Senior Partner, Torys LLP
Moderated by Howard R. Sklamberg, Partner, Arnold & Porter LLP
Virtual Learning FAQ